Glenmark Pharmaceuticals along with Mylan is reportedly planning to sell the generic versions of the drug Malarone, most successful anti-malarial medication in the UK. With UK court withdrawing GlaxoSmithKline’s patent on the drug, Glenmark Generics was able to launch the first generic version of the drug, Atovaquone proguanil, in the UK in early February.
This development came after Glenmark’s subsidiary, Glenmark Generics (Europe) and Mylan filed a case against The Welcome Foundation and Glaxo Group, for revocation of Glaxo’s patent for its anti-malarial product, Malarone.
Meanwhile, Atovaquone proguanil, which is the generic version of Malarone, is indicated for acute, uncomplicated falciparum malaria. Based on IMS Health sales data for the 12-month period ending September 2012, the drug had garnered sales of Euro 20.69 million in the UK.
GlaxoSmithKline, back in 2009, had filed a patent infringement lawsuit against Glenmark after the USFDA allowed the latter to market a generic version of the malaria drug. However, in April 2010, Glenmark settled the patent litigation with GlaxoSmithKline and was allowed to sell the generic tablets under a royalty bearing licence from GlaxoSmithKline in the third quarter of 2011, or earlier under certain circumstances.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: